The study, led by Amira Benattia of Université Paris Cité and the French National Reference Centre for Histiocytoses at Hôpital Saint-Louis in Paris, was published in BMC Medical Imaging as a prospective pilot investigation. Eighteen patients with cystic pulmonary Langerhans cell histiocytosis underwent paired inspiratory and expiratory CT scans alongside a battery of pulmonary function tests performed at the same visit. The researchers then ran the imaging data through three complementary quantitative analysis pipelines: conventional densitometry, parametric response mapping, and a vascular analysis tool known as CALIPER. The results, they report, demonstrate for the first time that these automated biomarkers are not only feasible in this rare disease but agree closely with expert visual scoring.

Pulmonary Langerhans cell histiocytosis is an uncommon interstitial lung disease, seen almost exclusively in smokers, in which abnormal immune cells accumulate in and around the small airways. Over time, the inflammation gives way to a distinctive pattern of nodules, cavities, and eventually thin-walled cysts scattered throughout the lungs. Because the disease is rare, large clinical trials are difficult to mount, and clinicians have lacked validated, objective tools to measure how much lung tissue is affected or how the damage progresses over time. Visual scoring systems exist, but they are inherently reader-dependent: two experienced radiologists looking at the same scan may grade the extent of disease differently, and the same reader may grade it differently on different days.

The Paris team attacked this problem with parametric response mapping, a technique originally developed for chronic obstructive pulmonary disease. The method works by co-registering inspiratory and expiratory CT scans of the same patient, voxel by voxel, and comparing lung density between the two breathing phases. Each tiny cube of lung tissue is then classified into one of three categories: normal density, persistent low-density areas that represent structurally destroyed tissue such as cysts and emphysema, and functional small airways disease, where air is trapped because the small bronchioles are narrowed or obstructed. In a disease like pulmonary Langerhans cell histiocytosis, where cystic destruction and small airway involvement coexist in the same lungs, this three-way classification promised something clinicians had never had: a way to separate the two processes quantitatively.

The findings were striking. Automated densitometry and parametric response mapping measurements of the cystic lesions correlated with expert visual scoring at correlation coefficients of at least 0.80 across the board, and the agreement between the automated and human assessments was excellent, with an intraclass correlation coefficient of 0.96 and a 95 percent confidence interval of 0.91 to 0.99. Just as importantly, the automated metrics tracked with physiology. The extent of persistent low-density tissue on CT correlated significantly with the diffusing capacity of the lungs for carbon monoxide, a standard pulmonary function measure that reflects how efficiently oxygen and carbon dioxide cross the delicate membrane between air and blood. In statistical terms, the numbers on the scan were telling the same story as the numbers on the breathing tests.

Perhaps the most intriguing result emerged when the researchers adjusted their analysis for smoking history, measured in pack-years. Because nearly all patients with this disease are smokers, and smoking itself causes emphysema and small airway damage, disentangling the effects of the histiocytosis from the effects of tobacco is a persistent challenge. In multivariate linear regression models adjusted for pack-years, the persistent low-density fraction measured by parametric response mapping remained significantly associated with all pulmonary function test parameters, independent of the functional small airways disease fraction. This suggests that the cystic destruction characteristic of the disease carries measurable functional consequences of its own, beyond whatever damage smoking has inflicted on the small airways.

The small airways story proved more complicated. The functional small airways disease values varied considerably among patients who had similar forced expiratory volume in one second percentages, a standard measure of airflow obstruction. The authors interpret this variability as evidence of genuine heterogeneity in small airway involvement across the patient population, rather than as a failure of the technique. In other words, two patients with the same overall airflow limitation may arrive there by different routes, one dominated by cystic destruction and another by widespread bronchiolar obstruction. If confirmed in larger cohorts, this kind of quantitative phenotyping could eventually help clinicians understand why some patients deteriorate rapidly while others remain stable for years, and could help stratify patients in future therapeutic trials.

The study also ventured beyond the airways and into the blood vessels. Using CALIPER, or Computer-Aided Lung Informatics for Pathology Evaluation and Rating, the team quantified pulmonary vascular volume, a surrogate measure of the blood vessel bed within the lungs. Vascular involvement is an increasingly recognized dimension of the disease, and the analysis revealed a significant inverse association between the regional extent of cystic destruction and pulmonary vascular volume, with a p-value of 0.002. Where the cysts were most extensive, the vascular tree was most depleted, a finding that fits with the understanding that the disease process destroys not only airspaces but also the capillary networks that supply them, potentially contributing to pulmonary hypertension, a feared complication of advanced disease.

None of this means automated imaging is ready to replace the radiologist tomorrow. The study was a pilot, involving eighteen patients at a single expert centre, and the authors are careful to frame their conclusions as proof of feasibility rather than validated clinical practice. The correlation and agreement statistics are encouraging, but the confidence intervals reflect a small sample, and the technique requires high-quality paired inspiratory-expiratory scans, careful co-registration, and standardized acquisition protocols that are not yet universal. The researchers themselves call for further evaluation of the biomarkers’ potential value for disease phenotyping and longitudinal assessment, the two applications where quantitative imaging could ultimately matter most.

Still, the significance of the work extends well beyond one rare disease. Quantitative CT biomarkers have transformed the study of common conditions like emphysema and idiopathic pulmonary fibrosis, enabling objective endpoints in drug trials and deeper understanding of disease subtypes. Rare diseases have largely been left out of that revolution, precisely because small patient populations make validation difficult. By demonstrating that parametric response mapping, densitometry, and vascular quantification can be applied successfully to pulmonary Langerhans cell histiocytosis, the Paris group has laid the methodological groundwork for the kind of rigorous, measurable, multi-centre research that rare disease patients have long been denied. For a condition where every patient counts, teaching machines to read the lungs with precision may prove to be more than a technical achievement; it may be the first step toward trials that can actually change outcomes.

Subject of Research: Automated quantitative CT imaging biomarkers for assessing pulmonary Langerhans cell histiocytosis

Article Title: Feasibility of automated quantitative CT imaging metrics in pulmonary Langerhans cell histiocytosis: a pilot study

Article References: Feasibility of automated quantitative CT imaging metrics in pulmonary Langerhans cell histiocytosis: a pilot study. (n.d.). https://doi.org/10.1186/s12880-026-02932-w

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02932-w

Keywords: pulmonary Langerhans cell histiocytosis, quantitative CT, parametric response mapping, densitometry, CALIPER, cystic lung disease, lung function, imaging biomarkers, pulmonary vascular volume, small airways disease, rare disease, radiology

SAD is the distance from the bed or floor to the highest point of the abdomen, essentially a measure of how deep the belly is rather than how wide. The rationale is anatomical: in a supine person, abdominal girth is influenced by subcutaneous fat, muscle tone, and even how much the abdominal wall relaxes, whereas the sagittal height is constrained by the spine behind and reflects the volume of the abdominal cavity, where visceral fat accumulates. Because visceral fat is metabolically active, releasing free fatty acids and inflammatory signaling molecules directly into the portal circulation, its burden correlates more tightly with insulin resistance, dyslipidemia, and fatty liver than overall body weight does. Imaging techniques such as computed tomography and magnetic resonance imaging quantify visceral fat precisely, but their cost and radiation exposure make them impractical for screening large populations.

The research team, led by Dandan Chen, Yimei Chen, and Qiwen Xiao with corresponding authors Liankun Zeng and Zhuoqing Hu, enrolled 1,881 adults in a cross-sectional study conducted in 2024. Rather than adopting a single measurement site, they systematically evaluated six candidate protocols. Supine measurements were taken at three anatomical landmarks: the midpoint between the lower edge of the ribcage and the top of the hip bone, the level of the navel, and the superior border of the iliac crest. The same three landmarks were then used with participants standing, producing six distinct values. This design allowed the investigators to determine, for the first time in a systematic head-to-head comparison, which combination of position and landmark best captured metabolic risk.

A key practical barrier to SAD measurement has always been instrumentation. Clinical studies have used sliding calipers, anthropometers, or specialized devices, none of which are widely available in routine clinics. The Guangzhou team designed a low-cost, simple L-shaped caliper specifically for the task, consisting of a horizontal base and a vertical arm whose height can be read directly. The device requires no power, no calibration beyond standard manufacturing tolerances, and minimal training, making it plausible to deploy in primary care settings, health screening centers, and community surveys where sophisticated equipment is out of reach.

The analytical strategy centered on correlations with metabolic indicators and on receiver operating characteristic, or ROC, analysis. ROC analysis quantifies how well a continuous measurement discriminates between people with and without a condition of interest; the area under the ROC curve, or AUC, ranges from 0.5, equivalent to a coin flip, to 1.0, perfect discrimination. In this study the diagnostic target was the presence of two or more non-adipose components of metabolic syndrome, meaning metabolic abnormalities other than waist size itself, such as elevated blood pressure, high fasting glucose, high triglycerides, or low HDL cholesterol. This choice deliberately tested whether each anthropometric measure could identify the metabolic consequences of central obesity rather than merely circling back to its own definition.

The results pointed clearly toward standing measurements. Standing SAD correlated more strongly with adverse metabolic indicators than supine SAD across the panel of biochemical and clinical variables. Within the standing set, the two measurements taken at the midpoint between the subcostal margin and the iliac crest, designated SAD4, and at the umbilical level, designated SAD5, showed the strongest correlations with metabolic markers and the highest AUCs for identifying central obesity. The physiological interpretation is that when a person stands, gravity pulls the abdominal contents downward, and the sagittal height at these mid-abdominal landmarks most faithfully reflects the volume of visceral fat pressing the abdominal wall forward, whereas supine measurements allow the contents to settle laterally and reduce the apparent depth.

When the researchers compared the best SAD protocols against waist circumference, the findings were striking in their consistency even if statistically modest. In the 2024 cohort, SAD4 and SAD5 yielded slightly higher AUCs than waist circumference in both women and men, though the differences did not reach statistical significance. To guard against overfitting to a single sample, the team pooled their data with a validation cohort of 701 adults recruited in 2023. In this combined analysis, SAD5 again showed slightly higher AUCs than waist circumference in both sexes, and this time the advantage reached statistical significance in men, with an AUC of 0.76 for SAD5 versus 0.74 for waist circumference, a difference with a P value of 0.03. The effect is small in absolute terms, but it was achieved with a measurement that takes seconds and avoids several known pitfalls of tape measurement.

Those pitfalls are worth spelling out, because they explain why the field has been searching for alternatives. Waist circumference depends on where the tape is placed, how tightly it is pulled, whether the subject exhales or holds their breath, and how much the subcutaneous fat layer compresses under tension. Inter-observer variability is well documented, and in people with very large abdomens the tape can sag or slip. SAD, by contrast, is a single-point height measurement with an unambiguous zero reference: the surface the person stands or lies on. The study established sex-specific optimal cutoffs for the umbilical-level standing measurement, finding that a value of 20.0 centimeters in women and 21.0 centimeters in men best discriminated central obesity in this Chinese population. These thresholds now provide clinicians with concrete numbers rather than a vague concept.

The authors recommend that, among Chinese adults, standing SAD measured at either the midpoint between the subcostal margin and the iliac crest or at the umbilical level should be used to identify metabolic risk factors. They position SAD as comparable or slightly superior to waist circumference, and as a potential simpler, novel tool for obesity assessment across a range of applications, from epidemiological surveys to routine health checkups. The L-shaped caliper design could be manufactured inexpensively at scale, and the measurement itself requires less training and produces fewer procedural ambiguities than tape-based girth. For large-scale screening in countries facing rising rates of type 2 diabetes and cardiovascular disease, a tool that is simultaneously cheap, fast, and at least as informative as the incumbent is a meaningful advance.

Important caveats remain before SAD can be adopted globally. The study was conducted in a Chinese population, and body proportions, fat distribution patterns, and existing waist circumference cutoffs differ across ethnic groups, so the authors explicitly call for validation in other populations. The reported advantage over waist circumference is slight, and in the initial cohort it did not reach statistical significance, so the most defensible current claim is equivalence with hints of superiority rather than a decisive win. It is also unknown how SAD performs in people with extreme obesity, spinal deformities, or large abdominal hernias, conditions that could distort the sagittal height. Nevertheless, the study delivers what the field has lacked: a standardized, reproducible protocol with defined landmarks, positions, and cutoffs, validated against metabolic outcomes in nearly 2,600 participants. If independent cohorts confirm these findings, the humble front-to-back belly measurement could become a routine vital sign of metabolic health, joining blood pressure and body mass index in the standard checkup.

Subject of Research: Standardized measurement of sagittal abdominal diameter for diagnosing central obesity and metabolic syndrome risk

Article Title: Standardization of sagittal abdominal diameter measurement: protocol evaluation and diagnostic utility for central obesity compared with waist circumference

Article References: Chen, D., Chen, Y., Xiao, Q., Li, C., Shi, W., Dong, P., Liang, W., Li, W., Zeng, L., & Hu, Z. (2026). Standardization of sagittal abdominal diameter measurement: protocol evaluation and diagnostic utility for central obesity compared with waist circumference. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02579-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02579-2

Keywords: sagittal abdominal diameter, central obesity, waist circumference, metabolic syndrome, visceral fat, anthropometry, ROC analysis, standardized protocol, caliper, cardiometabolic risk, screening, Guangzhou Medical University